Pharma BD Deal Intelligence
Sepracor's Latuda became a genuine blockbuster, reportedly peaking at $1.7B-$3.1B in annual US sales and carrying Dainippon Sumitomo for over a decade. But Lunesta went generic almost immediately in 2010, and Latuda's 2023 patent cliff crushed US sales to ~$645M, triggering a ¥354.9B group operating loss and mass layoffs—a high-amplitude boom-bust, not durable value creation.
Sepracor's Latuda became a true blockbuster that carried Dainippon Sumitomo for over a decade, but the 2023 patent cliff triggered a company-wide financial crisis, mass layoffs, and goodwill/patent impairments — leaving the deal's long-run verdict as a high-amplitude boom-bust rather than durable value creation.
Full analysis, sources & comparables →Deutsche Bank's David Steinberg said the deal would lift Dainippon to the #6 Japanese drugmaker; BMO Capital's Robert Hazlett said Sepracor's…
C&EN framed the takeover as Dainippon Sumitomo's entry vehicle into the US specialty market, leveraging Sepracor's Lunesta/Xopenex commercial muscle to launch…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
$23/share = ~$2.6B cash tender. CNS/respiratory specialty pharma (Lunesta, Xopenex). Closed Oct 20, 2009. Source: Sumitomo Pharma news, WilmerHale, Bloomberg.
Sepracor's Latuda became a true blockbuster that carried Dainippon Sumitomo for over a decade, but the 2023 patent cliff triggered a company-wide financial crisis, mass layoffs, and goodwill/patent impairments — leaving the deal's long-run verdict as a high-amplitude boom-bust rather than durable value creation.
Assessment window: 15yr post-close.
Sepracor's portfolio spanned chronic insomnia (Lunesta), reversible airway disease (Xopenex levalbuterol nebulizer/HFA, Brovana arformoterol for COPD), and a late-stage atypical antipsychotic (lurasidone) for schizophrenia. These are large, primary-care-and-specialist conditions in which differentiation typically comes from chiral purity, dosing, or tolerability rather than first-in-class biology.
By 2009 Lunesta (eszopiclone) faced intensifying competition in non-benzodiazepine hypnotics from generic zolpidem (Ambien), Ambien CR, and Takeda's Rozerem, with Lunesta sales already declining year-over-year. Xopenex levalbuterol generated ~$600M annually but was pressured by Medicare Part B reimbursement changes and racemic albuterol generics; Brovana competed with GSK's Serevent and Foradil in long-acting beta-agonists. The strategic prize for Dainippon Sumitomo was lurasidone (later Latuda), a Phase III atypical antipsychotic targeting D2/5-HT2A in schizophrenia, slotted against Eli Lilly's Zyprexa, AstraZeneca's Seroquel, J&J's Risperdal/Invega, and BMS/Otsuka's Abilify. The $23/share, ~$2.6B cash tender (28% premium) gave Dainippon Sumitomo an instant ~1,200-1,325 person US specialty sales force to launch lurasidone, which DSP otherwise would have had to build from scratch. Latuda was approved in October 2010 and became the franchise that justified the deal.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Dainippon Sumitomo Pharma Co., Ltd. / Sepracor Inc. (this deal) | 2009 | $2.6B | 63 |
| Dainippon Sumitomo Pharma Co., Ltd. / Boston Biomedical, Inc. | 2012 | $2.6B | 24 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| QIAGEN N.V. / DxS Ltd. | 2009 | $130M | 85 |
← Browse all deals · How we score deals
More: 2009 deals